We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




MRI-Guided Focused Ultrasound System Burns Breast Cancer Tumors without Surgery

By HospiMedica International staff writers
Posted on 11 Oct 2023

In a significant breakthrough in the field of non-invasive treatments for breast cancer, scientists have developed a technology capable of eliminating tumors without the need for surgical intervention, all within an outpatient setting. More...

The MUSE breast cancer treatment system developed by researchers from the Huntsman Cancer Institute at University of Utah Health (Salt Lake City, UT, USA) employs a two-step, non-surgical approach for locating and ablating, or removing, breast tumors. Initially, magnetic resonance imaging (MRI) is utilized to identify and pinpoint the tumors. Once the tumors are located, focused ultrasound technology is used to heat and subsequently destroy the cancerous cells. The entire treatment, which allows the patient to stay awake, takes about 90 minutes and is completed within a few hours.

Designed with patient comfort in mind, the MUSE system incorporates a special table for use during the MRI. The specialized device focuses ultrasound waves into a specific area of the tumor. These waves heat the cancerous tissue in intervals of 30 seconds, and are directed to cover the whole tumor. Currently in its phase 1 clinical trials, the first patient in the U.S. was treated using the MUSE system in a pioneering clinic trial in February 2023. The research team anticipates that it will take at least five years to advance through phase 3 clinical trials before MUSE becomes commercially available as a surgery-free option for treating breast cancer.

“The purpose of the current study is to see how well patients tolerate the ablation, basically how much pain they have during the procedure,” said Cindy Matsen, MD, breast surgeon at Huntsman Cancer Institute, who is the principal investigator for this clinical trial. “We’ll also be looking at the tissue after surgery to see how effective the ablation was. Only 50% is being ablated at this point to make sure we can still do tests that may be needed on the tumor afterwards. In the future, we hope this ablation will be effective enough to replace surgery for some women.”

Related Links:
University of Utah Health 


Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Xenon Light Source
CLV-S400
Pulmonary Ventilator
OXYMAG
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.